Back to Search
Start Over
Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced‐dose ibrutinib: results from a multi‐centre study.
- Source :
- British Journal of Haematology; Apr2018, Vol. 181 Issue 2, p259-261, 3p, 2 Graphs
- Publication Year :
- 2018
-
Abstract
- The article presents a study of chronic lymphocytic leukaemia patients treated with ibrutinib below the U.S. Food and Drug Administration-recommended starting dose to compare efficacy between the various dosing schedules. Topics discussed include the lack of significant differences in baseline characteristics between the standard-dose and reduced dose cohorts and reasons for ibrutinib dose reduction including gastrointestinal toxicity, bleeding and pharmacokinetic considerations.
Details
- Language :
- English
- ISSN :
- 00071048
- Volume :
- 181
- Issue :
- 2
- Database :
- Complementary Index
- Journal :
- British Journal of Haematology
- Publication Type :
- Academic Journal
- Accession number :
- 129077334
- Full Text :
- https://doi.org/10.1111/bjh.14540